<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">12-Week Treatment with LY2409021 Significantly Lowers HbA1C and Is Well Tolerated in Patients with Type 2 Diabetes Mellitus</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">16-17</style></pages><abstract><style  face="normal" font="default" size="100%">The glucagon receptor antagonist LY2409021 (LY) substantially lowers HbA1C without severe hypoglycemia or weight gain in type 2 diabetes mellitus (T2DM) patients. In a double-blind, randomized, placebo-controlled, Phase 2 study researchers examined the margin between LY efficacy and safety by comparing mean changes in HbA1C and liver aminotransferases at 3 dose levels.</style></abstract><number><style face="normal" font="default" size="100%">16</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>